Who is sponsoring NCT06314399?

NCT06314399 is sponsored by Hospital Universitario Mayor Méderi.

What drugs are being tested in NCT06314399?

Interventions in NCT06314399: Bile culture and phenotypic antibiogram resistance test.

What condition does NCT06314399 study?

NCT06314399 studies Biliary Infection, Antibiotic Resistant Strain.

Is NCT06314399 still recruiting?

NCT06314399 is currently completed. Last updated 18 March 2025.

Last reviewed 2025-03-18 · How we verify

NCT06314399: BACILO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictive Factors Associated to Bile Cultures and Antibiogram Resistance in Patients with Laparoscopic Cholecystectomy

Completed Last updated 18 March 2025

What this trial tests

trial testing Bile culture and phenotypic antibiogram resistance test in Biliary Infection in 703 participants. Completed in 24 December 2024.

Timeline

1 April 2024

Primary endpoint
26 October 2024

24 December 2024

Quick facts

Lead sponsor	Hospital Universitario Mayor Méderi
Status	Completed
Study type	OBSERVATIONAL
Enrollment	703
Start date	1 April 2024
Primary completion	26 October 2024
Estimated completion	24 December 2024
Sites	2 locations across Colombia

Drugs / interventions tested

Bile culture and phenotypic antibiogram resistance test

Conditions studied

Biliary Infection — all drugs for Biliary Infection →
Antibiotic Resistant Strain — all drugs for Antibiotic Resistant Strain →

Sponsor

Hospital Universitario Mayor Méderi

Who can join

18 and older, any sex, with Biliary Infection or Antibiotic Resistant Strain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The BACILO study was designed with the objective of having robust data on local epidemiological bacterial colonisation information on bile cultures with patients taken to laparoscopic cholecystectomy in our institution to find which predictive factors are associated with culture positivity and antibiotic resistance patterns. Secondary endpoints include evaluating demographical, clinical and surgical variables and establishing comparison between both positive and negative bile cultures and between antibiotic sensitive and resistant microorganism strain isolations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Predictive factors associated with Bile culture positivity And phenotypiCal antIbiogram resistance patterns in patients taken to LaparOscopic cholecystectomy (BACILO): protocol for a prospective observational cohort study and development of a prognostic prediction model.
Ramírez-Giraldo C, Rodriguez Barbosa C, Isaza-Restrepo A, Avendaño-Morales V, et al · · 2024 · cited 1× · PMID 39486833 · DOI 10.1136/bmjopen-2024-086655

Verify or expand the search:

Other Hospital Universitario Mayor Méderi trials

Trials by the same sponsor.

NCT07412379 — Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06314399 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Mayor Méderi
Last refreshed: 18 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06314399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing